RxDoctor Payments Data

Mallory Blessinger

Nurse Practitioner · Evansville, INNPI 1164154621

Payments from drug & device makers

$542in general payments, 2019–2025

Across 19 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$183
  • Otsuka America Pharmaceutical, Inc.$79
  • Alkermes, Inc.$76
  • Lundbeck LLC$55
  • AbbVie$37
  • E.r. Squibb & Sons, L.L.C.$33
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$542100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$542 in reported general payments places this provider in the 65th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$12,023
Medicare patients
45
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate12$29,341
Lurasidone Hcl16$22,713
VraylarCariprazine Hcl14$21,364
LatudaLurasidone Hcl13$16,934
Paliperidone ErPaliperidone28$15,228
Ziprasidone Hcl24$4,710
Atomoxetine Hcl11$3,036
Aripiprazole28$1,558
LoxapineLoxapine Succinate14$1,197
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$1,197
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$1,192
Bupropion XlBupropion Hcl78$1,121
Buspirone Hcl73$1,092
Clozapine25$921
Guanfacine Hcl ErGuanfacine Hcl34$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$183$29,34112 claims
AbbVieVraylar$37$21,36414 claims
Teva Pharmaceuticals USA, Inc.Loxapine$32$1,19714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →